PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.\', \'Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.\', \'University of Chinese Academy of Sciences, Beijing, 100049, China.\', \'Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.\', \'Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. xktong@simm.ac.cn.\', \'Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China. zhangbo@wh.iov.cn.\', \'Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. jpzuo@simm.ac.cn.\', \'University of Chinese Academy of Sciences, Beijing, 100049, China. jpzuo@simm.ac.cn.\', \'Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. jpzuo@simm.ac.cn.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41401-020-00556-6
?:doi
?:hasPublicationType
?:journal
  • Acta pharmacologica Sinica
is ?:pmid of
?:pmid
?:pmid
  • 33116249
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.173
?:rankingScore_hIndex
  • 73
is ?:relation_isRelatedTo_publication of
?:title
  • Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all